HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers

Simple item page
dc.article.number104100
dc.catalogadorgrr
dc.contributor.authorLynce, F.
dc.contributor.authorMartinez-Saez, O.
dc.contributor.authorWalbaum Garcia, Benjamin Vicente
dc.contributor.authorBraso-Maristany, F.
dc.contributor.authorWaks, A.G.
dc.contributor.authorVillagrasa, P.
dc.contributor.authorVillacampa, Javierre G.
dc.contributor.authorSanfeliu, E.
dc.contributor.authorGalvan, P.
dc.contributor.authorPare, L.
dc.contributor.authorAnderson, L.M.
dc.contributor.authorPerou, C.M.
dc.contributor.authorParker, J.S.
dc.contributor.authorVivancos, A.
dc.contributor.authorDiLullo, M.K.
dc.contributor.authorPernas, S.
dc.contributor.authorWiner, E.P.
dc.contributor.authorOvermoyer, B.
dc.contributor.authorMittendorf, E.A.
dc.contributor.authorBueno-Muino, C.
dc.contributor.authorMartin, M.
dc.contributor.authorPrat, A.
dc.contributor.authorTolaney, S.M.
dc.date.accessioned2025-04-30T15:26:53Z
dc.date.available2025-04-30T15:26:53Z
dc.date.issued2025
dc.description.abstractThe HER2DX assay predicts long-term prognosis and pathologic complete response (pCR) in patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving neoadjuvant systemic therapy but has not been evaluated in inflammatory breast cancer (IBC). Patients and methods: HER2DX was analyzed in baseline biopsy tissues from 23 patients with stage III HER2-positive IBC on a phase II trial (NCT01796197) treated with neoadjuvant trastuzumab, pertuzumab, and paclitaxel (THP). To assess the assay's predictive accuracy for pCR in IBC, clinical-pathological features and outcomes from this IBC cohort were compared with 156 patients with stage III HER2-positive non-IBC from four different cohorts. Comparative analyses included HER2DX scores, gene signatures, and expression of individual genes between patients with IBC and non-IBC. Results: Notable differences in clinicopathological characteristics included higher pertuzumab and chemotherapy usage and lower axillary burden in patients with IBC compared with non-IBC. In the combined cohort (n = 179), HER2DX pCR score and pertuzumab use were significant predictors of pCR, but not IBC status. The pCR rates in patients treated with trastuzumab-based chemotherapy (including IBC and non-IBC) were 68.9%, 58.5%, and 16.3% in the HER2DX pCR-high, -medium, and -low groups, respectively. Comparative gene expression analysis indicated minor differences between IBC and non-IBC affecting individual HER2, immune, and proliferation genes. Conclusions: The HER2DX pCR score could predict pCR in stage III HER2-positive IBC following treatment with de-escalated neoadjuvant systemic therapy and in stage III HER2-positive non-IBC. Elevated pCR rates in HER2-positive IBC with high HER2DX pCR scores suggest there may be a role for treatment de-escalation in these patients and confirmatory studies are justified.
dc.fechaingreso.objetodigital2025-04-30
dc.format.extent9 páginas
dc.fuente.origenSCOPUS
dc.identifier.doi10.1016/j.esmoop.2024.104100
dc.identifier.issn2059-7029
dc.identifier.pubmedid39826476
dc.identifier.scopusidSCOPUS_ID:85215086927
dc.identifier.urihttps://doi.org/10.1016/j.esmoop.2024.104100
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/103548
dc.information.autorucEscuela de Medicina; Walbaum Garcia, Benjamin Vicente; 0000-0003-2314-5360; 163702
dc.issue.numero2
dc.language.isoen
dc.nota.accesocontenido completo
dc.revistaESMO Open
dc.rightsacceso abierto
dc.rights.licenseCC BY-NC-ND 4.0 Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHER2-positive
dc.subjectHER2DX
dc.subjectInflammatory breast cancer
dc.subjectPathologic complete response
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleHER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers
dc.typeartículo
dc.volumen10
sipa.codpersvinculados163702
sipa.trazabilidadSCOPUS;2025-02-02
Files
Collections
Artículos de revistas